Docetaxel
About
Therapy type: Chemotherapy
Therapy strategy: Taxane-based chemotherapy
Mappings
NCI Thesaurus: Docetaxel (ncit:C1526)
Therapeutic response
Precision oncology relationships for therapeutic response involving this therapy.
| Organization(s) | Biomarker(s) | Cancer type | Therapy(ies) | |
|---|---|---|---|---|
| FDA (2) HC (5) | HER2-positive | Invasive Breast Carcinoma | Docetaxel, Pertuzumab, Trastuzumab | |
| FDA (4) HC (2) | HER2-positive | Invasive Breast Carcinoma | Cyclophosphamide, Docetaxel, Epirubicin, Fluorouracil, Pertuzumab, Trastuzumab | |
| FDA (2) HC (2) | HER2-positive | Invasive Breast Carcinoma | Cyclophosphamide, Docetaxel, Doxorubicin, Fluorouracil, Pertuzumab, Trastuzumab | |
| FDA (2) HC (2) | HER2-positive | Invasive Breast Carcinoma | Cyclophosphamide, Docetaxel, Epirubicin, Pertuzumab, Trastuzumab | |
| FDA (2) HC (2) | HER2-positive | Invasive Breast Carcinoma | Cyclophosphamide, Docetaxel, Doxorubicin, Pertuzumab, Trastuzumab | |
| FDA (2) HC (2) | HER2-positive | Invasive Breast Carcinoma | Carboplatin, Docetaxel, Pertuzumab, Trastuzumab | |
| HC (1) | HER2-positive | Invasive Breast Carcinoma | Carboplatin, Docetaxel, Trastuzumab | |
| HC (1) | HER2-positive | Invasive Breast Carcinoma | Docetaxel, Paclitaxel, Trastuzumab |